<DOC>
	<DOCNO>NCT02280486</DOCNO>
	<brief_summary>This multi-centre , open-label , randomize , parallel trial investigate efficacy safety profile saxagliptin glimepiride treatment patient type 2 diabetes inadequately control metformin monotherapy .</brief_summary>
	<brief_title>Safety Efficacy Saxagliptin vs.Glimepiride Add-on Therapy T2DM Patients With Metformin Monotherapytients</brief_title>
	<detailed_description>This multi-centre , open-label , randomize , parallel trial investigate efficacy safety profile saxagliptin glimepiride treatment patient type 2 diabetes inadequately control metformin monotherapy . Screening make select eligible participant intervention . The trial include 1-week run-in period stable dos metformin ( 1500mg ) 48-week treatment period . After run-in period , patient randomly assign one two group antihyperglycaemic therapy total 48-weeks : saxagliptin glimepiride . The treatment saxagliptin initiate maintain 5mg every morning completion study . Glimepiride initially treat 1 mg every morning , titrate 4-week interval reach target fast blood glucose ( FPG ) .As Glimepiride group , fast blood glucose dose achieve target maximal dos , maintain maximal dos ( 6mg per day ) completion study.Meanwhile , participant group take metformin 1500mg per day throughout whole 48 week . At end study , data collect analyzed .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>For inclusion study subject fulfill follow criterion : Provision inform consent prior study specific procedure Type2 diabetic patient stable , maximum tolerated dos metformin ( ≧1500mg/d , ≧8 week ) Male female age ≧ 25 year ≦75 year old HbA1c ≧7.0 ≦9.5 % BMI ≧ 20 ≦ 30 kg/m2 Subjects enter study follow exclusion criterion fulfil : Known suspect allergy trial product relate product . Impaired renal function define serumcreatinine ≥ 1.5 mg/dL ( ≥ 132.6 μmol/l ) . Acute chronic disease may cause tissue hypoxia cardiac respiratory failure , shock . Hepatic insufficiency , acute alcohol intoxication , alcoholism . Subjects clinically significant , active ( past 12 month ) cardiovascular history ( include history myocardial infarction ( MI ) , arrhythmias conduction delay ECG , unstable angina , decompensated heart failure ( New York Heart Associationclass Ⅲ Ⅳ ) . Proliferative retinopathy muscular oedema require acute treatment . Lactation . Pregnant positive pregnancy test screening , nurse mother , unwillingness use adequate contraception ( adequate contraceptive measure sterilization , intrauterine device , oral contraceptive barrier method ) . Treatment systemic corticosteroid within past two month prior screen . Tested positive glutamic acid decarboxylase antibody . Receipt investigational drug within 1 month prior trial .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>saxagliptin</keyword>
	<keyword>glimepiride</keyword>
	<keyword>metformin monotherapy</keyword>
</DOC>